# US 2003/0211122 A1 · Mucosal microparticle conjugate vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211122 A1
- Document ID: US20030211122A1
- Status: Published application
- Kind: A1
- Application number: 10/459,525
- Filed: 2003-06-12
- Published: 2003-11-13
- Earliest claimed: 1998-02-27
- Assignees: Innoventus Project AB
- Inventors: Ingvar Sjoholm; Lena Degling Wikingsson
- Web page: https://patentgrep.com/patent/US20030211122A1

## CPC

- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6927: {the form being a solid microparticle having no hollow or gas-filled cores}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Mucosal, particularly oral, microparticle conjugate vaccines against certain pathogenic microorganisms, especially intracellular pathogenic microorganisms, are disclosed. An immunizing component of such a vaccine comprises protection-generating antigens derived from a certain pathogenic microorganism, such as Mycobacterium tuberculosis or Salmonella enteritidis, conjugated, possibly via a linker, to biodegradable microparticles, particularly starch microparticles, such as cross-linked starch microparticles, e.g. polyacryl starch microparticles. Further, a method of inducing protective immunity against a certain pathogenic microorganism in a mammal, and the use of protection-generating antigens derived from a certain pathogenic microorganism conjugated, possibly via a linker to biodegradable microparticles for the production of a mucosal microparticle conjugate vaccine are described.

## Claims

### Claim 1

Mucosal microparticle conjugate vaccine against a certain pathogenic microorganism, which comprises, as an immunizing component, a T-cell activating amount of protection-generating antigens derived from said microorganism conjugated, possibly via a linker, to biodegradable microparticles.

### Claim 2 (depends on 1)

Vaccine according to claim 1, wherein the biodegradable microparticles are starch particles, including cross-linked starch particles.

### Claim 3 (depends on 2)

Vaccine according to claim 2, wherein the cross-linked starch particles are polyacryl starch microparticles.

### Claim 4 (depends on 1, 2, 3)

Vaccine according to any one of claims 1-3, wherein the mucosal vaccine is an oral vaccine.

### Claim 5 (depends on 1, 2, 3, 4)

Vaccine according to any one of claims 1-4, wherein the pathogenic microorganism is an intracellular pathogenic microorganism.

### Claim 6 (depends on 5)

Vaccine according to claim 5, wherein said intracellular pathogenic microorganism is selected from the group consisting of Mycobacterium tuberculosis and Salmonella enteritidis.

### Claim 7

Method of inducing protective immunity against a certain pathogenic microorganism in a mammal, including man, comprising mucosal administration to said mammal of a T-cell activating amount of protection-generating antigens derived from said microorganism conjugated, possibly via a linker, to biodegradable microparticles, as an immunizing component.

### Claim 8 (depends on 7)

Method according to claim 7, wherein the mucosal administration is oral administration and the protection-generating antigens derived from said microorganism are secreted proteins from Mycobacterium tuberculosis or Salmonella enteritidis

### Claim 9

Use of protection-generating antigens derived from a certain pathogenic microorganism conjugated, possibly via a linker, to biodegradable microparticles for the production of a mucosal microparticle conjugate vaccine against said certain pathogen.

### Claim 10 (depends on 7)

Use according to claim 7, wherein the mucosal vaccine is an oral vaccine, said antigens derive from Mycobacterium tuberculosis or Salmonella enteritidis, and the biodegradable microparticles are starch particles, including cross-linked starch particles and polyacryl starch microparticles.
